EQUIPMENT AND METHOD FOR METERING INSTILLED LIQUID CRYSTALS

The present disclosure provides an equipment and method for metering instilled liquid crystals, so as to improve the metering accuracy and the metering efficiency of the equipment for metering instilled liquid crystals. The equipment includes a tray having a plurality of holes arranged in a circle and a measuring cup arranged within each hole, a pair of scales arranged below the circle of the holes, and a driving device connected to the tray in a driving manner and configured to drive the tray to move up and down and drive the tray that has moved to a high position to rotate to a position where one measuring cup to be metered is in alignment with the pair of scales. 1. An equipment for metering instilled liquid crystals , comprising:a tray having a plurality of holes arranged in a circle and a measuring cup being arranged within each hole;a pair of scales arranged below the circle of the holes; anda driving device connected to the tray in a driving manner and configured to drive the tray to move up and down;wherein when the tray moves to a high position, the driving device is further configured to drive the tray to rotate to a position where one of the measuring cups to be metered is in alignment with the pair of scales.2. The equipment according to claim 1 , wherein there are at least two pairs of scales claim 1 , and a number of the holes in the tray is an integral multiple of a number of pairs of the scales.3. The equipment according to claim 2 , wherein the holes are arranged at a regular interval in the circle; the at least two pairs of scales are arranged below the circle of the holes at a regular interval.4. The equipment according to claim 1 , further comprising a vibration sensor and a vibration compensator;wherein the vibration sensor is configured to detect vibration information of the pair of scales; andthe vibration compensator is in communication with the vibration sensor, and configured to, when an electric signal corresponding to the vibration ...

LIQUID CRYSTAL DISPLAY PANEL POOR ALIGNMENT REPAIRING APPARATUS

A liquid crystal display panel poor alignment repairing apparatus includes: a shell including an accommodation space which includes a separate first chamber and a separate second chamber; and a temperature control device, which is to control temperatures in the first chamber and the second chamber in such a manner of heating a to-be-repaired liquid crystal display panel in the first chamber and simultaneously cooling a to-be-repaired liquid crystal display panel in the second chamber.

FIXING PIECE CONNECTING TO A PHOTO FRAME BACKING BOARD AND MANUFACTURING METHOD THEREOF

A fixing piece connecting to a photo frame backing board, comprising a rotating portion and a fixed portion connected with a photo frame. One end of the rotating portion is connected with the fixed portion. Another end is connected with a fixed body used for fixing the photo frame; the rotating portion is formed by engaging and connecting a concave rotational surface and a convex rotational surface. A method for manufacturing the aforementioned fixing piece connecting to a photo frame backing board is also provided. 1. A fixing piece connecting to a photo frame backing board , comprising a rotating portion and a fixed portion connected with a photo frame; one end of the rotating portion is connected with the fixed portion; another end of the rotating portion is connected with a fixing body used for fixing the photo frame;the rotating portion is formed by engaging and connecting a concave rotational surface and a convex rotational surface; the convex rotational surface of the rotating portion is connected with the fixed portion; the concave rotational surface is connected with the fixing body; a through hole is provided at a center of the concave rotational surface; the fixed portion connected with the convex rotational surface passes through the through hole; the convex rotational surface is sleeved within the concave rotational surface so as to be fitted and connected together; the concave rotational surface limits the convex rotational surface so that the convex rotational surface is only capable of rotating within and relative to the concave rotational surface but not able to slip off from the concave rotational surface; the concave rotational surface limits the convex rotational surface by the following configuration: after the concave rotational surface has sleeved the convex rotational surface, an outer site of the concave rotational surface is processed to form a flange wherein an inner diameter of the flange is smaller than an outer diameter of the convex ...

QUALITY-OF-EXPERIENCE MEASUREMENT FOR VOICE SERVICES

Technologies are generally described for determining a quality-of-experience (QoE) of a network communication. In some examples, a process for determining a QoE metric for a network communication includes receiving a media signal from the network communication. The process may also include extracting an experience indicator from the media signal, wherein the experience indicator corresponds to a participant's subjective usage experience associated with a service quality of the network communication, and determining the QoE metric for the network communication based on the experience indicator and a quality-of-service (QoS) metric for the network communication. 1. A method for determining a quality-of-experience (QoE) metric for a network communication , comprising:receiving a media signal from the network communication;extracting an experience indicator from the media signal, wherein the experience indicator corresponds to a participant's subjective usage experience associated with a service quality of the network communication; anddetermining the QoE metric for the network communication based on the experience indicator and a quality-of-service (QoS) metric for the network communication.2. The method as recited in claim 1 , wherein the determining of the QoE metric further comprisingupon a determination that the experience indicator illustrating the service quality of the network communication is subpar, retrieving the QoS metric for the network communication; andupon a determination that the QoS metric illustrating the service quality of the network communication is subpar, calculating the QoE metric.3. The method as recited in claim 1 , wherein the experience indicator is a voice feature descriptive of the service quality of the network communication.4. The method as recited in claim 1 , wherein the voice feature is an emotion-change amplitude measurement.5. The method as recited in claim 1 , wherein the voice feature is a voice-pacing time measurement.6. The ...

Cancer Therapy with a Parvovirus Combined with an HDAC Inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma. 1. Pharmaceutical composition containing (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI).2. The pharmaceutical composition of containing (a) a parvovirus and (b) an HDCAI as separate entities.3. The pharmaceutical composition according to claim 1 , wherein said parvovirus is H-1 (H-1PV) or a related rodent parvovirus.4. The pharmaceutical composition according to claim 3 , wherein said related rodent parvovirus is LuIII claim 3 , Mouse minute virus (MMV) claim 3 , Mouse parvovirus (MPV) claim 3 , Rat minute virus (RMV) claim 3 , Rat parvovirus (RPV) or Rat virus (RV).5. The pharmaceutical composition according to claim 1 , wherein said HDACI is sodium butyrate (NaB) claim 1 , trichostatin A (TSA) claim 1 , Valproic acid (VPA) or suberoylanilide hydroxamic acid (SAHA).6. Use of a parvovirus and an HDACI as defined in for the preparation of (a) pharmaceutical composition(s) for the treatment of cancer.7. The use of claim 6 , wherein (a) the parvovirus and (b) the HDACI are sequentially administered.8. The use according to claim 7 , wherein the parvovirus (a) is administered prior to the HDACI (b).9. The use according to claim 6 , wherein said cancer is a brain tumor claim 6 , cervical carcinoma claim 6 , or pancreatic carcinoma.10. The use according to claim 9 , wherein said brain tumor is a glioma claim 9 , medulloblastoma or meningioma.11. The use according to claim 10 , wherein said glioma is a malignant human glioblastoma.12. The use according to claim 6 , wherein said parvovirus is administered by intratumoral administration.13. The pharmaceutical composition of for use in a method for the treatment of cancer.14. The pharmaceutical composition according to claim 13 , wherein said cancer is a brain tumor claim 13 ...

HYDROPHILIC AND NON-THROMBOGENIC POLYMER FOR COATING OF MEDICAL DEVICES

A hydrophilic copolymer is designed and synthesized by copolymerization of an acidic monomer and a second hydrophilic monomer. The copolymer is non-thrombogenic, hydrophilic and incorporates reactive functional groups. The copolymer can then be covalently attached to a primer/base coat through its functional groups, to form a durable lubricious coating on medical devices. A coating formed of the polymer on a surface is non-thrombogenic and non-cytotoxic. The coating shows good stability in gamma ray, e-beam and ethylene oxide sterilization. 1. A coating composition comprising a copolymer formed by copolymerizing 5 to 95% by weight of non-ionizable hydrophilic ethylenic monomers , 5 to 95% by weight of acidic group-containing ethylenic monomers , and a balance comprising other ethylenic monomers.2. The composition of claim 1 , wherein the non-ionizable claim 1 , hydrophilic monomers are selected from the group consisting of hydroxyl-group containing ethylenic monomers and aprotic claim 1 , hydrophilic ethylenic monomers.3. The composition of claim 1 , wherein a portion of the acidic group-containing ethylenic monomers is neutralized.4. The composition of claim 1 , wherein said acid group-containing ethylenic monomers are selected from the group consisting of acrylic acid claim 1 , methacrylic acid claim 1 , 2-ethylacrylic acid claim 1 , 2-propylacrylic acid claim 1 , acryloxypropionic acid claim 1 , isocrotonic acid claim 1 , maleic anhydride claim 1 , maleic acid and half esters claim 1 , half amides and half thioesters of maleic acid claim 1 , fumaric acid and itaconic acid claim 1 , and any mixture of the foregoing.5. The composition of claim 1 , wherein said hydroxylic group-containing ethylenic monomers are selected from the group consisting of N-(2-hydroxyethyl)acrylamide claim 1 , 2-hydroxyethyl methacrylate claim 1 , 2-hydroxypropyl acrylate claim 1 , 2-hydroxypropyl methacrylate claim 1 , 2 claim 1 ,4-dihydroxy-4′-vinyl benzophenone claim 1 , and N-(2- ...

QUALITY-OF-EXPERIENCE MEASUREMENT FOR VOICE SERVICES

An example method to determine a quality-of-experience (QoE) metric for a network communication includes receiving a media signal from the network communication, wherein the media signal includes a voice component, extracting an experience indicator from the voice component, wherein the experience indicator is a voice feature descriptive of a service quality of the network communication, evaluating the experience indicator, retrieving a quality-of-service (QoS) metric if the evaluated experience indicator reflects the service quality of the network possibly being subpar, and determining the QoE metric for the network communication based on the evaluated experience indicator and the retrieved QoS metric for the network communication. 1. A method to determine a quality-of-experience (QoE) metric for a network communication , comprising:receiving a media signal from the network communication, wherein the media signal includes a voice component;extracting an experience indicator from the voice component, wherein the experience indicator is a voice feature descriptive of a service quality of the network communication;evaluating the experience indicator;retrieving a quality-of-service (QoS) metric if the evaluated experience indicator reflects the service quality of the network possibly being subpar; anddetermining the QoE metric for the network communication based on the evaluated experience indicator and the retrieved QoS metric for the network communication.2. The method as recited in claim 1 , wherein the voice feature is an emotion-change amplitude measurement.3. The method as recited in claim 1 , wherein the voice feature is a voice-pacing time measurement.4. The method as recited in claim 1 , wherein the voice feature is a sound-volume pitch measurement.5. The method as recited in claim 1 , wherein the voice feature is a corpus.6. The method as recited in claim 1 , further comprising detecting the voice component in the media signal based on zero-crossing rate.7. ...

ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS

Methods for forming an expandable tubular body having a plurality of braided filaments including a first filament including platinum or platinum alloy and a second filament including cobalt-chromium alloy. The methods include applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament and applying a silane material on the second filament followed by a second phosphorylcholine material on the silane material on the second filament. The first and second phosphorylcholine materials each define a thickness of less than 100 nanometers. 1. A medical device , comprising:a ventricular assist device (VAD) having a surface comprising an outermost layer of phosphorylcholine,wherein the outermost layer of phosphorylcholine has a thickness of less than 100 nanometers.2. The medical device of claim 1 , wherein the VAD comprises at least one of steel claim 1 , aluminum claim 1 , titanium claim 1 , cobalt claim 1 , chromium claim 1 , platinum claim 1 , nickel claim 1 , alloys thereof claim 1 , or combinations thereof.3. The medical device of claim 1 , wherein the phosphorylcholine is selected from the group consisting of 2-methacryloyloxyethyl phosphorylcholine claim 1 , 2-acryloyloxyethyl phosphorylcholine claim 1 , and phosphorylcholines based upon monomers including 2-(meth)acryloyloxyethyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 3-(meth)acryloyloxypropyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 4-(meth)acryloyloxybutyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 5-(meth)acryloyloxypentyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 6-(meth)acryloyloxyhexyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxyethyl-2′-(triethylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxyethyl-2′-(tripropylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxyethyl-2′-(tributylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxypropyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxybutyl-2 ...

Cancer Therapy with a Parvovirus Combined with an HDAC Inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma. 15.-. (canceled)6. A method of treating cancer comprising the administration of a pharmaceutical composition containing (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI).7. The method of claim 6 , wherein (a) the parvovirus and (b) the HDACI are sequentially administered.8. The method of claim 7 , wherein the parvovirus (a) is administered prior to the HDACI (b).9. The method of claim 6 , wherein said cancer is a brain tumor claim 6 , cervical carcinoma claim 6 , or pancreatic carcinoma.10. The method of claim 9 , wherein said brain tumor is a glioma claim 9 , medulloblastoma or meningioma.11. The method of claim 10 , wherein said glioma is a malignant human glioblastoma.12. The method of claim 6 , wherein said parvovirus is administered by intratumoral administration.13. (canceled)14. (canceled)15. The method of claim 6 , wherein the parvovirus is selected from the group consisting of (H-1PV) claim 6 , LuIII claim 6 , Mouse minute virus (MMV) claim 6 , Mouse parvovirus (MPV) claim 6 , Rat minute virus (RMV) claim 6 , Rat parvovirus (RPV) claim 6 , and Rat virus (RV).16. The method of claim 6 , wherein the HDACI is selected from the group consisting of sodium butyrate (NaB) claim 6 , trichostatin A (TSA) claim 6 , Valproic acid (VPA) or suberoylanilide hydroxamic acid (SAHA).17. A method of treating cervical carcinoma or pancreatic carcinoma comprising the administration of an effective dose of a pharmaceutical composition containing (a) a H-1 parvovirus (H-1PV) and (b) a histone deacetylase inhibitor (HDACI) selected from the group consisting of valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) claim 6 , wherein said effective dose comprises an amount sufficient to lead to the reduction or remission of ...

INJECTABLE SCAFFOLD FOR TREATMENT OF INTRACRANIAL ANEURYSMS AND RELATED TECHNOLOGY

A method for treating an aneurysm in accordance with a particular embodiment of the present technology includes intravascularly delivering a mixture including a biopolymer (e.g., chitosan) and a chemical crosslinking agent (e.g., genipin) to an aneurysm. The method further includes mixing the biopolymer and the chemical crosslinking agent to initiate chemical crosslinking of the biopolymer. The mixture is delivered to the aneurysm via a lumen and an exit port of a catheter while the chemical crosslinking is ongoing. The mixture exits the catheter as a single cohesive strand that at least partially agglomerates to form a mass occupying at least 75% of a total internal volume of the aneurysm. During delivery of the mixture, the method includes expanding a tubular flow diverter to reinforce a neck of the aneurysm. 1. A method for treating an aneurysm , the method comprising:intravascularly advancing a catheter toward an aneurysm at a portion of a blood vessel, wherein the catheter includes an elongate lumen and an exit port at a distal end portion of the lumen;mixing a biopolymer and a chemical crosslinking agent to initiate chemical crosslinking of the biopolymer;flowing the biopolymer and the chemical crosslinking agent toward an internal volume of the aneurysm via the lumen while the chemical crosslinking is ongoing; anddelivering the biopolymer and the chemical crosslinking agent from the lumen into the internal volume via the exit port while the chemical crosslinking is ongoing.2. The method of wherein the aneurysm is an intracranial aneurysm.3. The method of wherein:the biopolymer has a non-zero degree of chemical crosslinking before being mixed with the chemical crosslinking agent; andmixing the biopolymer and the chemical crosslinking agent includes mixing the biopolymer and the chemical crosslinking agent to increase the degree of chemical crosslinking.4. The method of wherein delivering the biopolymer and the chemical crosslinking agent from the lumen into ...

ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS

Methods for forming an expandable tubular body having a plurality of braided filaments including a first filament including platinum or platinum alloy and a second filament including cobalt-chromium alloy. The methods include applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament and applying a silane material on the second filament followed by a second phosphorylcholine material on the silane material on the second filament. The first and second phosphorylcholine materials each define a thickness of less than 100 nanometers. 1. A medical device , comprising: a substrate comprising at least one of cobalt, cobalt alloy, chromium, chromium alloy, nickel, or nickel alloy;', 'a silane material on the substrate; and', 'a phosphorylcholine material on the silane material,', 'wherein the phosphorylcholine material defines a thickness of less than 100 nanometers, and, 'a braided vascular device comprising a plurality of braided filaments, wherein the braided vascular device is configured to be implanted in a blood vessel, and wherein at least some respective filaments of the plurality of braided filaments comprise a time elapsed before onset of thrombin formation that is greater than about 1.5 times a time elapsed before onset of thrombin formation of a similar braided vascular device without the phosphorylcholine material,', 'a time elapsed before peak thrombin formation that is less than about 0.8 times a time elapsed before peak thrombin formation of a similar braided vascular device without the phosphorylcholine material, or', 'a peak thrombin concentration that is less than about 0.8 times a peak thrombin concentration of a similar braided vascular device without the phosphorylcholine material., 'wherein the braided vascular device exhibits at least one of2. The medical device of claim 1 , wherein the braided vascular device exhibits the time elapsed before onset of thrombin formation that is greater than about 1.5 ...

CANCER THERAPY WITH A PARVOVIRUS COMBINED WITH A BCL-2 INHIBITOR

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199. 1. A pharmaceutical composition comprising: (a) a parvovirus; and (b) a Bcl-2 inhibitor , wherein said parvovirus is H-1 (H-1PV) or a related rodent parvovirus selected from the group consisting of LuIII , Mouse minute virus (MMV) , Mouse parvovirus (MPV) , Rat minute virus (RMV) , Rat parvovirus (RPV) and Rat virus (RV).2. The pharmaceutical composition of claim 1 , wherein the parvovirus and the Bcl-2 inhibitor are separate entities.3. The pharmaceutical composition according to claim 1 , wherein said Bcl-2 inhibitor is ABT-737 or ABT-199.4. A method of treating cancer comprising administering the parvovirus and Bcl-2 inhibitor as defined in any one of to to a patient in need thereof.5. The method of claim 4 , wherein the parvovirus and the Bcl-2 inhibitor are sequentially administered.6. The method of claim 4 , wherein the cancer comprises a solid tumor and/or cancer initiating stem cell.7. The method of claim 4 , wherein the cancer comprises tumors resistant to parvovirus cytotoxicity.8. The method of claim 4 , wherein the cancer comprises a tumor claim 4 , wherein said tumor is a brain tumor claim 4 , pancreatic carcinoma claim 4 , cervical carcinoma claim 4 , lung cancer claim 4 , head and neck cancer claim 4 , breast cancer or colon cancer.9. The method of claim 4 , wherein the cancer comprises a glioma or recurrent glioblastoma multiforme.10. The method of claim 4 , wherein the parvovirus and/or the Bcl-2 inhibitor are administered by intratumoral administration. This application is a continuation-in-part application of international patent application Serial No. PCT/EP2014/002001 filed Jul. 22, 2014, which published as PCT Publication No. WO 2015/010782 A1 on Jan. 29, 2015, which claims benefit of European patent ...

INJECTABLE SCAFFOLD FOR TREATMENT OF INTRACRANIAL ANEURYSMS AND RELATED TECHNOLOGY

A method for treating an aneurysm in accordance with a particular embodiment of the present technology includes intravascularly delivering a mixture including a biopolymer (e.g., chitosan) and a chemical crosslinking agent (e.g., genipin) to an aneurysm. The method further includes mixing the biopolymer and the chemical crosslinking agent to initiate chemical crosslinking of the biopolymer. The mixture is delivered to the aneurysm via a lumen and an exit port of a catheter while the chemical crosslinking is ongoing. The mixture exits the catheter as a single cohesive strand that at least partially agglomerates to form a mass occupying at least 75% of a total internal volume of the aneurysm. During delivery of the mixture, the method includes expanding a tubular flow diverter to reinforce a neck of the aneurysm. 1. A method for treating an aneurysm , the method comprising:intravascularly advancing a catheter toward an aneurysm at a portion of a blood vessel, wherein the catheter includes an elongate lumen and an exit port at a distal end portion of the lumen;mixing a biopolymer and a chemical crosslinking agent to initiate chemical crosslinking of the biopolymer;flowing the biopolymer and the chemical crosslinking agent toward an internal volume of the aneurysm via the lumen while the chemical crosslinking is ongoing; anddelivering the biopolymer and the chemical crosslinking agent from the lumen into the internal volume via the exit port while the chemical crosslinking is ongoing.2. The method of wherein the aneurysm is an intracranial aneurysm.3. The method of wherein:the biopolymer has a non-zero degree of chemical crosslinking before being mixed with the chemical crosslinking agent; andmixing the biopolymer and the chemical crosslinking agent includes mixing the biopolymer and the chemical crosslinking agent to increase the degree of chemical crosslinking.4. The method of wherein delivering the biopolymer and the chemical crosslinking agent from the lumen into ...

CANCER THERAPY WITH A PARVOVIRUS COMBINED WITH A BCL-2 INHIBITOR

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199. 1. A pharmaceutical composition comprising: (a) a parvovirus; and (b) a Bcl-2 inhibitor , wherein said parvovirus is H-1 (H-1PV) or a related rodent parvovirus selected from the group consisting of LuIII , Mouse minute virus (MMV) , Mouse parvovirus (MPV) , Rat minute virus (RMV) , Rat parvovirus (RPV) and Rat virus (RV).2. The pharmaceutical composition of claim 1 , wherein the parvovirus and the Bcl-2 inhibitor are separate entities.3. The pharmaceutical composition according to claim 1 , wherein said Bcl-2 inhibitor is ABT-737 or ABT-199.4. A method of treating cancer claim 1 , wherein the method comprises administering a parvovirus and a Bcl-2 inhibitor to a patient in need thereof.5. The method of claim 4 , wherein the parvovirus and the Bcl-2 inhibitor are sequentially administered.6. The method of claim 4 , wherein the cancer comprises a solid tumor and/or cancer initiating stem cell.7. The method of claim 4 , wherein the cancer comprises tumors resistant to parvovirus cytotoxicity.8. The method of claim 4 , wherein the cancer comprises a tumor claim 4 , wherein said tumor is a brain tumor claim 4 , pancreatic carcinoma claim 4 , cervical carcinoma claim 4 , lung cancer claim 4 , head and neck cancer claim 4 , breast cancer or colon cancer.9. The method of claim 4 , wherein the cancer comprises a glioma or recurrent glioblastoma multiforme.10. The method of claim 4 , wherein the parvovirus and/or the Bcl-2 inhibitor are administered by intravenous or intratumoral administration.11. The method of claim 4 , wherein said parvovirus is H-1 (H-1PV) or a related rodent parvovirus selected from the group consisting of LuIII claim 4 , Mouse minute virus (MMV) claim 4 , Mouse parvovirus (MPV) claim 4 , Rat minute virus (RMV) claim 4 , ...

DEVICES, SYSTEMS, AND METHODS FOR TREATMENT OF INTRACRANIAL ANEURYSMS

Systems and methods for treating an aneurysm in accordance with embodiments of the present technology include intravascularly delivering an occlusive member to an aneurysm cavity and deforming a shape of the occlusive member via introduction of an embolic element to a space between the occlusive member and an inner surface of the aneurysm wall. 1. A device for treating an aneurysm , the device comprising:a mesh having an expanded, unconstrained state, the mesh formed of a plurality of braided filaments, each of the filaments having a first end and a second end, wherein the mesh has a proximal portion configured to be positioned over the neck of an aneurysm and a distal portion;a first coupler at the proximal portion, wherein the first ends are secured relative to one another at the first coupler; anda second coupler at the distal portion, wherein the second ends are secured relative to one another at the second coupler,wherein the mesh is formed of a wall comprising a first portion, a second portion, and a ridge, wherein the first portion extends between the first coupler and the ridge and the second portion extends between the ridge and the second coupler, andwherein the mesh includes a cavity at the distal portion, and wherein all or a portion of the distal coupler is positioned within the cavity.2. The device of claim 1 , wherein the mesh has a single layer delivery configuration.3. A method for imaging treatment of an aneurysm claim 1 , the method comprising:acquiring a first image visualizing:an occlusive member positioned within an aneurysm, the occlusive member including a first radiopaque marker; anda conduit having a distal portion positioned within an aneurysm, the distal portion of the conduit including a second radiopaque marker; andacquiring a second image in which the first radiopaque marker is further from the second radiopaque marker than in the first image.4. The method of claim 3 , wherein claim 3 , in the second image claim 3 , the first ...

ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS

Methods for forming an expandable tubular body having a plurality of braided filaments including a first filament including platinum or platinum alloy and a second filament including cobalt-chromium alloy. The methods include applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament and applying a silane material on the second filament followed by a second phosphorylcholine material on the silane material on the second filament. The first and second phosphorylcholine materials each define a thickness of less than 100 nanometers. 125-. (canceled)26: A medical device , comprising: a substrate comprising at least one of cobalt, cobalt alloy, chromium, chromium alloy, nickel, or nickel alloy;', 'a silane layer comprising a silane material on the substrate; and', 'an outer coating comprising a phosphorylcholine material on the silane layer, wherein the outer coating defines a layer thickness of less than 10 nanometers., 'a braided vascular device comprising a plurality of braided filaments, wherein the braided vascular device is configured to be implanted in a blood vessel, and wherein at least some respective filaments of the plurality of braided filaments comprise27: The medical device of claim 26 , wherein the silane material comprises at least one of 3-glycidoxypropyltrimethoxysilane claim 26 , 2-(3 claim 26 ,4-epoxycyclohexyl)ethyltriethoxysilane claim 26 , 2-(3 claim 26 ,4-epoxycyclohexyl)ethyl-trimethoxysilane claim 26 , (3-glycidoxypropyl)trimethoxysilane claim 26 , (3-glycidoxypropyl)triethoxysilane claim 26 , 5 claim 26 ,6-epoxyhexyltriethoxysilane claim 26 , (3-glycidoxypropyl)methyldiethoxysilane claim 26 , (3-glycidoxypropyl)methyldimethoxysilane claim 26 , (3-glycidoxypropyl)dimethylethoxysilane claim 26 , 3-isocyanatopropyltriethoxysilane claim 26 , (isocyanatomethyl)methyldimethoxysilane claim 26 , 3-isocyanatopropyltrimethoxysilane claim 26 , tris(3-trimethoxysilylpropyl)isocyanurate claim 26 , (3- ...

Fixing piece connecting to a photo frame backing board and manufacturing method thereof

A fixing piece connecting to a photo frame backing board, comprising a rotating portion and a fixed portion connected with a photo frame. One end of the rotating portion is connected with the fixed portion. Another end is connected with a fixed body used for fixing the photo frame; the rotating portion is formed by engaging and connecting a concave rotational surface and a convex rotational surface. A method for manufacturing the aforementioned fixing piece connecting to a photo frame backing board is also provided.

Coated medical devices

Processes for coating medical devices are provided herein. The processes include contacting a substrate with a sulfur-functional silane and an additional silane. The resulting coating includes a silane layer having improved adherence to the medical device, covering a greater area.

ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS

Methods for applying layers to medical devices and related devices are provided. Such devices can include stents. For example, the device can include a sidewall and a plurality of pores in the sidewall that are sized to inhibit flow of blood through the sidewall into an aneurysm to a degree sufficient to lead to thrombosis and healing of the aneurysm when the tubular member is positioned in a blood vessel and adjacent to the aneurysm. The device can have an anti-thrombogenic outer layer distributed over at least a portion of the device. 1. A medical device , comprising:an expandable tubular body comprising a plurality of braided filaments configured to be implanted in a blood vessel, the braided filaments comprising a metal selected from the group consisting of platinum, cobalt, chromium, nickel, alloys thereof, and combinations thereof;wherein the filaments have an outer surface comprising a phosphorylcholine; andwherein the phosphorylcholine has a thickness of less than 100 nanometers.2. The medical device of claim 1 , wherein the phosphorylcholine is selected from the group consisting of 2-methacryloyloxyethyl phosphorylcholine claim 1 , 2-acryloyloxyethyl phosphorylcholine claim 1 , and phosphorylcholines based upon monomers including 2-(meth)acryloyloxyethyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 3-(meth)acryloyloxypropyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 4-(meth)acryloyloxybutyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 5-(meth)acryloyloxypentyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 6-(meth)acryloyloxyhexyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxyethyl-2′-(triethylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxyethyl-2′-(tripropylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxyethyl-2′-(tributylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxypropyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 2-(meth)acryloyloxybutyl-2′-(trimethylammonio)ethyl phosphate claim 1 , 2-(meth) ...

Universal Influenza Vaccine

The present invention includes an isolated antigen against influenza A and a method of making the same that includes an ectodomain of influenza A Matrix Protein 2 (M2e) and a stem region of an influenza A hemagglutinin 2 (HA2) protein and an adjuvant. The invention further includes formulating the antigen into an isolated immune response stimulating fusion protein and/or a vaccine.

TISSUE CATALYZED GROWTH OF POLYMER AS EPITHELIAL LININGS FOR THERAPY

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder. 1. A method of forming a polymer in situ in a subject , the method comprising administering to a subject a composition comprising a monomer and an oxygen source , wherein the monomer and the oxygen source contact a catalyst endogenous to the subject and the catalyst polymerizes the monomer , wherein the monomer is dopamine , or a salt thereof , the oxygen source is hydrogen peroxide or urea hydrogen peroxide , and the endogenous catalyst is selected from a catalase or a peroxidase.2. The method of claim 1 , wherein the peroxidase is eosinophil peroxidase claim 1 , lactoperoxidase claim 1 , or myeloperoxidase.3. The method of claim 1 , wherein the endogenous catalyst is a catalase.4. (canceled)5. The method of claim 1 , wherein the endogenous catalyst is located in the gastrointestinal (GI) tract of the subject.67-. (canceled)8. The method of claim 1 , wherein the composition further comprises an enzyme claim 1 , a nutrient blocker claim 1 , a nutraceutical claim 1 , a radioprotective agent claim 1 , an active pharmaceutical ingredient claim 1 , a diagnostic agent claim 1 , or a combination thereof.9. The method of claim 1 , wherein the composition is administered orally to the subject.1015-. (canceled)16. The method of claim 1 , wherein the composition comprises about 0.01 to about 50 mg/mL of dopamine.1720-. (canceled)21. The method of claim 1 , wherein the composition comprises about 1 to about 30 mM of the oxygen source.22. (canceled)23. The method of claim 1 , wherein the composition has a pH of about 7 to about 10.2428-. (canceled)29. The method of claim 1 , wherein the polymer forms in contact with the epithelium of the ...

INJECTABLE BIOPOLYMER COMPOSITIONS AND ASSOCIATED SYSTEMS AND METHODS

Injectable biopolymer compositions and associated systems and methods are disclosed herein. In some embodiments, a biopolymer composition for treating an aneurysm is provided. The biopolymer composition can include an injectable hydrogel including: a biopolymer; a chemical crosslinker forming covalent bonds with the biopolymer; and a stabilizer configured to inhibit ex vivo precipitation of the biopolymer. The injectable hydrogel can have an ex vivo storage modulus of at least 100 Pa at 37° C. over a linear viscoelastic region of the injectable hydrogel. The ex vivo storage modulus can be greater than an ex vivo loss modulus of the injectable hydrogel over the linear viscoelastic region of the injectable hydrogel. 1111.-. (canceled)112. A biopolymer composition for treating an aneurysm , the biopolymer composition comprising: a biopolymer;', 'a chemical crosslinker forming covalent bonds with the biopolymer; and', 'a stabilizer configured to inhibit ex vivo precipitation of the biopolymer, wherein the injectable hydrogel comprises an ex vivo storage modulus of at least 100 Pa', 'at 37° C. over a linear viscoelastic region of the injectable hydrogel., 'an injectable hydrogel comprising113. The biopolymer composition of claim 112 , wherein the injectable hydrogel is configured to occlude the aneurysm without undergoing a phase transition upon exposure to in vivo conditions.114. The biopolymer composition of claim 112 , wherein the biopolymer comprises a chitosan comprising a viscosity of at least 50 Pa-s when measured as a 1% (w/v) solution at 20° C. and a shear rate of 1/s.115. The biopolymer composition of claim 112 , wherein the injectable hydrogel comprises no more than 9% (w/v) of the biopolymer.116. The biopolymer composition of claim 112 , wherein the chemical crosslinker comprises one or more of the following: genipin claim 112 , glutaraldehyde claim 112 , formaldehyde claim 112 , diethyl squarate claim 112 , blocked diisocyanate claim 112 , ethylene glycol ...

DEVICES, SYSTEMS, AND METHODS FOR TREATMENT OF INTRACRANIAL ANEURYSMS

Systems and methods for treating an aneurysm in accordance with embodiments of the present technology include intravascularly delivering an occlusive member to an aneurysm cavity via an elongated shaft and transforming a shape of the occlusive member within the cavity. The method may include introduction of an embolic element to a space between the occlusive member and an inner surface of the aneurysm wall. In some embodiments, the elongated shaft is detachably coupled to a distal portion of the occlusive member. 1. A system comprising:an elongate shaft defining a lumen;an elongate member slidably disposed within the lumen of the elongate shaft, the elongate member having a proximal end region and a distal end region, wherein the distal end region is configured to be intravascularly position at or within an aneurysm cavity;an occlusive member constrained within the lumen of the shaft, the occlusive member including a proximal end portion having an opening and a distal end portion detachably coupled to the distal end region of the elongate member, wherein the elongate member extends through the opening such that thewherein pushing the elongate member from a distal opening in the elongate shaft pulls the occlusive member distally through the distal opening to expel the occlusive member from the shaft and allow the occlusive member to expand to an expanded state.2. The system of claim 1 , further comprising an embolic element configured to be delivered to the aneurysm cavity through the elongate member while the elongate member is coupled to the distal end portion of the occlusive member.3. The system of claim 2 , wherein the embolic element is a liquid embolic claim 2 , one or more embolic coils claim 2 , or both.4. The system of claim 1 , wherein a portion of the occlusive member surrounding the elongate member at the opening is configured to slide relative to the elongate member as the occlusive member self-expands.5. The system of claim 1 , wherein the occlusive ...

PACKAGING APPARATUS

Embodiments of the present invention provide a packaging apparatus, which relates to a preparing field of display technology and can solve a problem of the poor bonding state between a packaging cover plate and a substrate to be packaged, improving a quality of assembled product. The packaging apparatus comprises: an upper sealing unit and a lower sealing unit which have recesses and are movable towards each other to engage and form a cavity, wherein upper suction columns for fixing a packaging cover plate is disposed inside the recess of the upper sealing unit and a bearing table for bearing a substrate to be packaged is disposed inside the recess of the lower sealing unit, and seal glue is disposed on a face of the substrate to be packaged facing the packaging cover plate; a suction mechanism for vacuumizing the cavity; a leveling mechanism for adjusting a levelness of the packaging cover plate and/or the substrate to be packaged; a displacing mechanism for driving the packaging cover plate and/or the substrate to be packaged to move towards each other so that the packaging cover plate contacts the seal glue; an inflation mechanism for filling gas into the cavity after vacuumizing. 1. A packaging apparatus comprising:an upper sealing unit and a lower sealing unit which have recesses and are movable towards each other to engage and form a cavity, wherein upper suction columns for fixing a packaging cover plate are disposed inside the recess of the upper sealing unit and a bearing platform for bearing a substrate to be packaged is disposed inside the recess of the lower sealing unit, and seal glue is disposed on a face of the substrate to be packaged facing the packaging cover plate;a suction mechanism for vacuumizing the cavity;a leveling mechanism for adjusting a levelness of the packaging cover plate and/or the substrate to be packaged;a displacing mechanism for driving the packaging cover plate and/or the substrate to be packaged to move towards each other so ...

Live Attenuated Viral Vaccine Created by Self-Attenuation With Species-Specific Artificial MicroRNA

The present invention includes a live attenuated virus and methods of making the same comprising an isolated virus comprising a viral genome that expresses one or more viral antigens; and one or more exogenous species-specific microRNAs inserted into the viral genome and expressed thereby, wherein the species-specific microRNAs are ubiquitously expressed in a viral target species cell but not in a viral propagation cell.

ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS

Methods for forming an expandable tubular body having a plurality of braided filaments including a first filament including platinum or platinum alloy and a second filament including cobalt-chromium alloy. The methods include applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament and applying a silane material on the second filament followed by a second phosphorylcholine material on the silane material on the second filament. The first and second phosphorylcholine materials each define a thickness of less than 100 nanometers. 1. A method comprising:forming an expandable tubular body comprising a plurality of braided filaments, the expandable tubular body is configured to be implanted in a blood vessel, the plurality of braided filaments comprising a first filament comprising platinum or platinum alloy and a second filament comprising cobalt-chromium alloy;applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament;applying a silane material to the second filament comprising the cobalt-chromium alloy, wherein the silane material comprises a silane selected from the group consisting of 3-glycidoxypropyltrimethoxysilane, 2-(3,4-epoxycyclohexyl)ethyltriethoxysilane, 2-(3,4-epoxycyclohexyl)ethyl-trimethoxysilane, (3-glycidoxypropyl)trimethoxysilane, (3-glycidoxypropyl)triethoxysilane, 5,6-epoxyhexyltriethoxysilane, (3-glycidoxypropyl)methyldiethoxysilane, (3-glycidoxypropyl)methyldimethoxysilane, (3-glycidoxypropyl)dimethylethoxysilane, 3-isocyanatopropyltriethoxysilane, (isocyanatomethyl)methyldimethoxysilane, 3-isocyanatopropyltrimethoxysilane, tris(3-trimethoxysilylpropyl)isocyanurate, (3-triethoxysilylpropyl)-t-butylcarbamate, triethoxysilylpropylethylcarbamate, 3-thiocyanatopropyltriethoxysilane, and combinations thereof; andapplying a second phosphorylcholine material on the silane material on the second filament,wherein the first and second phosphorylcholine ...

Dual Purpose Universal Influenza Vaccine Confers Protective Immunity Against Anthrax

The present invention includes antigenic fusion proteins, nucleic acids encoding the fusion proteins and methods of making and using the same, wherein the fusion protein comprises three or more different influenza A ectodomains of Matrix Protein 2 (M2e); one or more stem regions of an influenza A hemagglutinin 2 (HA2) protein; and optionally an anthrax antigen, wherein the fusion protein is immunogenic across strains. 1. An antigenic fusion protein comprising:three or more different influenza A ectodomains of matrix protein 2 (M2e) domains; one or more stem regions of an influenza A hemagglutinin 2 (HA2) protein domains; and optionally an anthrax antigen, wherein the fusion protein is immunogenic across influenza strains.2. The fusion protein of claim 1 , wherein the fusion protein further comprises claim 1 , or is provided with claim 1 , an adjuvant selected from at least one of cholera toxin B subunit claim 1 , flagellin claim 1 , human papillomavirus L1 or L2 protein claim 1 , herpes simplex glycoprotein D (gD) claim 1 , complement C4 binding protein claim 1 , TL4 ligand claim 1 , and 1L-1 beta claim 1 , aluminum salt claim 1 , Freund's complete or incomplete adjuvant claim 1 , lysolecithin claim 1 , pluronic polyols claim 1 , polyanions claim 1 , an oil-water emulsion claim 1 , dinitrophenol claim 1 , iscomatrix claim 1 , and liposome polycation DNA particles.3. The fusion protein of claim 1 , wherein influenza A ectodomains are selected from H1N1 claim 1 , H3N2 claim 1 , or H5N1.4. The fusion protein of claim 1 , further comprises the stem region of the influenza A hemagglutinin 2 (HA2) protein.5. The fusion protein of claim 1 , wherein the antigen is formulated into a vaccine.6. The fusion protein of claim 1 , wherein the antigen is formulated into a vaccine further adapted for intraperitoneal claim 1 , subcutaneous claim 1 , intranasal claim 1 , intramuscular claim 1 , oral claim 1 , topical or transdermal administration.7. The fusion protein of claim 1 , ...

METHODS AND SYSTEMS FOR CALCULATING STATISTICAL QUANTITIES IN A COMPUTING ENVIRONMENT

This disclosure is directed to methods and systems for calculating statistical quantities of computational resources used by distributed data sources in a computing environment. In one aspect, a master node receives a query regarding use of computational resources used by distributed data sources of a computing environment. The data sources generate metric data that represents use of the computational resources and distribute the metric data to two or more worker nodes. The master node directs each worker node to generate worker-node data that represents the metric data received by each of the worker nodes and each worker node sends worker-node data to the master node. The master node receives the worker-node data and calculates a master-data structure based on the worker-node data, which may be used to estimate percentiles of the metric data in response to the query. 1. A method stored in one or more data-storage devices and executed using one or more processors of a computing environment , the method comprising:receiving a query at a master node about use of computational resources of the computing environment;distributing metric data to one or more worker nodes, the metric data represents use of the computational resources; receiving the query from the master node,', 'generating worker-node data that represents the metric data received by the worker node in response to the query, and', 'sending the worker-node data to the master node; and, 'each worker node'}calculating at the master node a master-data structure that represents a distribution of the metric data over data-structure intervals based on the worker-node data sent from the worker nodes.2. The method of further comprises calculating estimated percentiles from the master-data structure based on the query.3. The method of claim 1 , wherein distributing the metric data further comprises:generating the metric data at data sources of the computing environment that use the computational resources;partitioning ...

H-1 PV EXPRESSING RNAI EFFECTORS TARGETING CDK9

The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs, against the CDK9 gene which display improved anticancer activity. These new viruses are based on the ΔH-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (ΔH-IPV) and harbouring a shRNA expression cassette in which the expression of the shRNA is controlled by the HI Polymerase III promoter. In this invention the inventors aimed to use the ΔH-1PVsilencer to silence the CDK9 gene whose activity is often dysregulated in cancer cells and known to contribute to tumorigenesis. The present invention also provides cells or organisms comprising said parvovirus. 1. Parvovirus for down regulating the expression of cyclin dependent kinase 9 (CDK9) in a cell characterized in that it is derived from a parvovirus H-1 deletion variant containing a deletion encompassing the nucleotides 2022-2135 , wherein a CDK9 specific nucleic acid is inserted in an untranslated region downstream of the H-1 parvovirus VP gene and is expressible under the control of a promoter or promoter region recognizable by an RNA polymerase in the cell , wherein said CDK9 specific nucleic acid is transcribable in an RNAi , and wherein said parvovirus is capable of replicating and propagating in the cell.2. The parvovirus of claim 1 , wherein the CDK9 specific nucleic acid is inserted at nucleotide 4683 of the H-1PV genome.3. The parvovirus of claim 1 , wherein the promoter or promoter region recognizable by a RNA polymerase of the cell is an RNA-polymerase II (Pol II) or III (Pol III) promoter.4. The parvovirus of claim 3 , wherein the RNA-polymerase III (Pol III) promoter is the RNA-polymerase III H1 promoter.5. The parvovirus of claim 1 , wherein CDK9 specific nucleic acid is an shRNA.6. The parvovirus of claim 1 , wherein the CDK9 specific nucleic acid has a length of at least 15 nucleotides.7. The parvovirus of claim 5 , wherein the ...

Detergent recommendation method and equipment

The present disclosure belongs to the technical field of smart homes, and particularly relates to a detergent recommendation method and equipment. The detergent recommendation method of the present disclosure includes: obtaining usage numbers respectively corresponding to various types of washing programs used by a user where the various types of washing programs respectively correspond to different types of detergents, selecting N types of washing programs with a maximum usage number from various types of washing programs according to the usage numbers, and pushing a prompt information of detergents respectively corresponding to the N types of the washing programs to the user, and can preferentially recommend the detergent suitable for the washing program with higher operating frequency to the user based on the usage number of the user using different washing programs.

H-1 pv expressing rnai effectors targeting cdk9

The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs, against the CDK9 gene which display improved anticancer activity. These new viruses are based on the ??-lPVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (??-IPV) and harbouring a shRNA expression cassette in which the expression of the shRNA is controlled by the HI Polymerase III promoter. In this invention the inventors aimed to use the ??-lPVsilencer to silence the CDK9 gene whose activity is often dysregulated in cancer cells and known to contribute to tumorigenesis. The present invention also provides cells or organisms comprising said parvovirus.

Anti-thrombogenic medical devices and methods

Methods for forming an expandable tubular body having a plurality of braided filaments including a first filament including platinum or platinum alloy and a second filament including cobalt-chromium alloy. The methods include applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament and applying a silane material on the second filament followed by a second phosphorylcholine material on the silane material on the second filament. The first and second phosphorylcholine materials each define a thickness of less than 100 nanometers.

Cancer therapy with a parvovirus combined with an hdac inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.

ANTITROMBOGENIC MEDICAL DEVICES AND METHODS

dispositivos e métodos médicos antitrombogênicos. a presente invenção refere-se a métodos para aplicar camadas em dispositivos médicos, e dispositivos relacionados são fornecidos. tais dispositivos podem incluir stents. por exemplo, o dispositivo pode incluir uma parede lateral e uma pluralidade de poros na parede lateral, que são dimensionados para inibir o fluxo de sangue através da parede lateral para um aneurisma a um grau suficiente para levar a trombose e a cura do aneurisma quando o membro tubular é posicionado em um vaso sanguíneo e adjacente ao aneurisma. o dispositivo pode ter uma camada exterior antitrombogênica distribuída sobre pelo menos uma porção do dispositivo. antithrombogenic medical devices and methods. the present invention relates to methods for applying layers to medical devices, and related devices are provided. such devices may include stents. for example, the device may include a sidewall and a plurality of pores on the sidewall, which are sized to inhibit blood flow through the sidewall to an aneurysm to a degree sufficient to lead to thrombosis and aneurysm healing when the tubular limb is positioned in a blood vessel and adjacent to the aneurysm. the device may have an outer antithrombogenic layer distributed over at least a portion of the device.

Devices, systems, and methods for treating aneurysms

Occlusive devices and associated methods of manufacturing are disclosed herein. Manufacturing an occlusive device can include conforming a mesh to a forming assembly and setting a shape of the mesh based on the forming assembly. In some embodiments, the forming assembly comprises multiple forming members, a mandrel, and/or one or more coupling elements. The method may include everting the mesh over the forming assembly such that the mesh encloses an open volume with a shape based, at least in part, on the shape of the forming assembly. According to some embodiments, setting a shape of the mesh comprises heat-treating the mesh and forming assembly.

Devices, systems, and methods for treatment of intracranial aneurysms

Systems and methods for treating an aneurysm in accordance with embodiments of the present technology include intravascularly delivering an occlusive member to an aneurysm cavity and deforming a shape of the occlusive member via introduction of an embolic element to a space between the occlusive member and an inner surface of the aneurysm wall.

Cancer therapy with a parvovirus combined with a bcl-2 inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199.

Method of manufacturing anti-thrombogenic medical devices

The invention provides a method comprising: forming an expandable tubular body comprising a plurality of braided filaments, wherein the expandable tubular body is configured to be implanted in a blood vessel, and wherein the plurality of braided filaments comprises a first filament comprising platinum or platinum alloy and a second filament comprising cobalt-chromium alloy; chemically bonding a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament; applying a silane intermediate layer on the second filament comprising the cobalt-chromium alloy; and applying a second phosphorylcholine material on the silane intermediate layer on the second filament, wherein the first and second phosphorylcholine materials each define a respective thickness of less than 100 nanometers.

Cancer therapy with a parvovirus combined with an HDAC inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.

Tissue catalyzed growth of polymer as epithelial linings for therapy

The present disclosure provides compositions, methods, and kits that enable the

Mr-signal emitting coatings

The present invention provides a method of manufacturing a magnetic-resonance-imageable medical device, the method comprising: providing a medical device; and cross-linking a chain with a first hydrogel to form a hydrogel overcoat on at least a portion of the medical device, the chain having a paramagnetic-metal-ion/chelate complex linked thereto, wherein the chain is part of a polymer or part of a hydrogel, a solid-base polymer, a polymer that is not covalently linked to the medical device or a second hydrogel.

Devices, systems, and methods for treatment of intracranial aneurysms

Systems and methods for treating an aneurysm in accordance with embodiments of the present technology include intravascularly delivering an occlusive member to an aneurysm cavity via an elongated shaft and transforming a shape of the occlusive member within the cavity. The method may include introduction of an embolic element to a space between the occlusive member and an inner surface of the aneurysm wall. In some embodiments, the elongated shaft is detachably coupled to a distal portion of the occlusive member.

Tissue catalyzed growth of polymer as epithelial linings for therapy

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

MR SIGNAL TRANSMITTER COATINGS

Injectable scaffold for treatment of intracranial aneurysms and related technology

A method for treating an aneurysm in accordance with a particular embodiment of the present technology includes intravascularly delivering a mixture including a biopolymer (e.g., chitosan) and a chemical crosslinking agent (e.g., genipin) to an aneurysm. The method further includes mixing the biopolymer and the chemical crosslinking agent to initiate chemical crosslinking of the biopolymer. The mixture is delivered to the aneurysm via a lumen and an exit port of a catheter while the chemical crosslinking is ongoing. The mixture exits the catheter as a single cohesive strand that at least partially agglomerates to form a mass occupying at least 75% of a total internal volume of the aneurysm. During delivery of the mixture, the method includes expanding a tubular flow diverter to reinforce a neck of the aneurysm.

Mr-signal emitting coatings

Injector devices for delivering material to vascular defects and associated systems and methods

Systems, methods, and devices for treating vascular defects are disclosed herein. In some embodiments, a method of treating an aneurysm includes positioning a distal portion of an elongated member near or within an aneurysm. The method can include introducing an embolic composition into a lumen of the elongated member using an injector device coupled to a proximal portion of the elongated member. The injector device can pressurize the embolic composition to a pressure of at least 10,000 psi. The method can also include delivering the embolic composition into the aneurysm via the elongated member.

Devices, systems, and methods for treatment of intracranial aneurysms

Systems and methods for treating an aneurysm in accordance with embodiments of the present technology include intravascularly delivering an occlusive member to an aneurysm cavity via an elongated shaft and transforming a shape of the occlusive member within the cavity. The method may include introduction of an embolic element to a space between the occlusive member and an inner surface of the aneurysm wall. In some embodiments, the elongated shaft is detachably coupled to a distal portion of the occlusive member.

Gastroretentive articles for alcohol sensing

Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).

Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199.

Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199.

Devices, systems, and methods for treatment of intracranial aneurysms

Systems and methods for treating an aneurysm in accordance with embodiments of the present technology include intravascularly delivering an occlusive member to an aneurysm cavity and deforming a shape of the occlusive member via introduction of an embolic element to a space between the occlusive member and an inner surface of the aneurysm wall.

Aneurysm treatment device

Treatment of aneurysms can be improved by use of a treatment system including a conduit have a distal portion, a coupler slidably coupled to the distal portion, an occlusive member coupled to the coupler, and a securing member coupled to the conduit proximal to the coupler. The securing member can include a distal end portion that is removably coupled to the coupler. In some embodiments, the securing member can have a shape and/or be treated such that the securing member self-expands to decouple itself from the coupler during deployment of the occlusive member. In some embodiments, movement of the conduit relative to the coupler causes the securing member to decouple from the coupler.

Synthetic tissue barriers and uses thereof

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide a broad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

Systems and methods for treating aneurysms

Treatment of aneurysms can be improved by delivering an occlusive member (e.g., an expandable braid) to an aneurysm sac in conjunction with an embolic element (e.g., coils, embolic material). A treatment system for such treatment can include an electrolytically corrodible conduit having a proximal portion, a distal portion, and a detachment zone between the proximal portion and the distal portion. An occlusive member having a proximal hub is coupled to the conduit distal portion. The conduit has a lumen configured to pass an embolic element therethrough. An inner electrode assembly can be slidably disposed within the conduit lumen to facilitate electrolytic detachment of the occlusive member at the detachment zone.

H-1 pv expressing rnai effectors

The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs against the PD-L1 gene which display improved anticancer activity. These new viruses are based on the ?H-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (?H-1PV) and harbouring a shRNA expression cassette in which the expression of the shRNA is controlled by the H1 Polymerase III promoter. In this invention the inventors aimed to use the ?H-1PVsilencer to silence the PD-L1 gene. PD1/PD-L1 negatively regulates T cell-mediated immune responses and serves as a mechanism for tumors to escape antigen-specific T cell immune responses. The present invention also provides cells or organisms comprising said parvovirus.

Anti-h1n1 subtype influenza virus nanoparticles based on self-assembled ferritin, preparation method and application thereof

Disclosed are an anti-H1 N1 subtype influenza virus nanoparticles based on self-assembled 5 ferritin, a preparation method and an application thereof, and relate to the technical field of genetic engineering. The nanoparticles are formed by connecting a signal peptide-ST-FE fusion protein and a signal peptide-SC-HA-VHH fusion protein in vitro; the signal peptide-ST-FE fusion protein is obtained by connecting a signal peptide-SpyTag shown in SEQ ID NO: 3 to an N-terminal of a ferritin monomer subunit; the signal peptide-SC-HA-VHH fusion protein is obtained by connecting 10 the N-terminal of nano antibody against hemagglutinin protein of influenza type A (H1 N1) subtype virus with a signal peptide-SpyCatcher shown in SEQ ID NO: 4. The anti-H1 N1 subtype influenza virus nanoparticles of the present invention are of great significance for monitoring, prevention and treatment of the H1 N1 subtype influenza virus.

Detergent recommendation method and device

Anti-thrombogenic medical devices and methods

Methods for forming an expandable tubular body having a plurality of braided filaments including a first filament including platinum or platinum alloy and a second filament including cobalt-chromium alloy. The methods include applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament and applying a silane material on the second filament followed by a second phosphorylcholine material on the silane material on the second filament. The first and second phosphorylcholine materials each define a thickness of less than 100 nanometers.

Devices, systems, and methods for treating aneurysms

Devices, systems, and methods for treating aneurysms are disclosed herein. According to some embodiments, the present technology includes a treatment system comprising a delivery shaft, a manipulation shaft slidably positioned within the lumen of the delivery shaft, and an occlusive device configured for implantation within the aneurysm. The occlusive device can comprise a plurality of filaments that are secured to one another at a proximal end of the occlusive device by a cured material. The occlusive device can comprise inner and outer layers of braided filaments, wherein the proximal end region of the inner layer has an exposed portion that extends proximally beyond the proximal end region of the outer layer, and wherein the cured material extends into and fills interstices between the braided filaments at the proximal end regions of the inner and outer layers.

Injectable biopolymer compositions and associated systems and methods

Injectable biopolymer compositions and associated systems and methods are disclosed herein. In some embodiments, a biopolymer composition for treating an aneurysm is provided. The biopolymer composition can include an injectable hydrogel including: a biopolymer; a chemical crosslinker forming covalent bonds with the biopolymer; and a stabilizer configured to inhibit ex vivo precipitation of the biopolymer. The injectable hydrogel can have an ex vivo storage modulus of at least 100 Pa at 37 °C over a linear viscoelastic region of the injectable hydrogel. The ex vivo storage modulus can be greater than an ex vivo loss modulus of the injectable hydrogel over the linear viscoelastic region of the injectable hydrogel.

Gastroretentive articles for alcohol sensing

Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).

Devices, systems, and methods for treating aneurysms

Devices, systems, and methods for treating aneurysms are disclosed herein. According to some embodiments, the present technology includes a treatment system comprising a delivery shaft, a manipulation shaft slidably positioned within the lumen of the delivery shaft, and an occlusive device configured for implantation within the aneurysm. The occlusive device can comprise a plurality of filaments that are secured to one another at a proximal end of the occlusive device by a cured material. The occlusive device can comprise inner and outer layers of braided filaments, wherein the proximal end region of the inner layer has an exposed portion that extends proximally beyond the proximal end region of the outer layer, and wherein the cured material extends into and fills interstices between the braided filaments at the proximal end regions of the inner and outer layers.

Occlusive devices for treating vascular defects and associated systems and methods

Systems, methods, and devices for treating vascular defects are disclosed herein. In some embodiments, a device for treating an aneurysm includes a plurality of braided filaments configured to be implanted in an aneurysm cavity.

Systems and methods for treating aneurysms

Treatment of aneurysms can be improved by delivering an occlusive member (e.g., an expandable braid) to an aneurysm sac in conjunction with an embolic element (e.g., coils, embolic material). A treatment system for such treatment can include an electrolytically corrodible core wire having a proximal portion, a distal portion, and a detachment zone between the proximal portion and the distal portion. An occlusive member having a proximal hub is coupled to the core wire distal portion. A conduit extends along at least a portion of the core wire. The conduit has a lumen configured to pass an embolic element therethrough.

Injectable scaffold for treatment of intracranial aneurysms and related technology

A method for treating an aneurysm in accordance with a particular embodiment of the present technology includes intravascularly delivering a mixture including a biopolymer (e.g., chitosan) and a chemical crosslinking agent (e.g., genipin) to an aneurysm. The method further includes mixing the biopolymer and the chemical crosslinking agent to initiate chemical crosslinking of the biopolymer. The mixture is delivered to the aneurysm via a lumen and an exit port of a catheter while the chemical crosslinking is ongoing. The mixture exits the catheter as a single cohesive strand that at least partially agglomerates to form a mass occupying at least 75% of a total internal volume of the aneurysm. During delivery of the mixture, the method includes expanding a tubular flow diverter to reinforce a neck of the aneurysm.

Injectable scaffold for treatment of intracranial aneurysms and related technology

A method for treating an aneurysm in accordance with a particular embodiment of the present technology includes intravascularly delivering a mixture including a biopolymer (e.g., chitosan) and a chemical crosslinking agent (e.g., genipin) to an aneurysm. The method further includes mixing the biopolymer and the chemical crosslinking agent to initiate chemical crosslinking of the biopolymer. The mixture is delivered to the aneurysm via a lumen and an exit port of a catheter while the chemical crosslinking is ongoing. The mixture exits the catheter as a single cohesive strand that at least partially agglomerates to form a mass occupying at least 75% of a total internal volume of the aneurysm. During delivery of the mixture, the method includes expanding a tubular flow diverter to reinforce a neck of the aneurysm.

一种变压器噪声测量机器人

本实用新型公开了一种变压器噪声测量机器人，包括具有转向功能的机器人、噪声传感器和距离传感器，机器人上竖直安装有电动推杆，噪声传感器安装在电动推杆的推杆上端，传感器的探头正对变压器，电动推杆的推杆上端还安装有距离传感器。本实用新型通过机器人带着噪声传感器在变压器周围按照设定轨迹进行行走测量，能够实现变压器的远距离噪声测量，降低人身触电的风险。而且，经过程序设定，机器人可通过距离传感器适时调整机器人与变压器的水平距离，并采用电动推杆，根据测试需求适时调整噪声探头的高度，以适应变压器不同高度与不同距离的噪声测量，通过上述技术，实现噪声探头的距离与高度的精准控制，从而确保变压器噪声测量的安全性与准确性。

Devices, systems, and methods for treating aneurysms

Occlusive devices and associated methods of manufacturing are disclosed herein. Manufacturing an occlusive device can include conforming a mesh to a forming assembly and setting a shape of the mesh based on the forming assembly. In some embodiments, the forming assembly comprises multiple forming members, a mandrel, and/or one or more coupling elements. The method may include everting the mesh over the forming assembly such that the mesh encloses an open volume with a shape based, at least in part, on the shape of the forming assembly. According to some embodiments, setting a shape of the mesh comprises heat-treating the mesh and forming assembly.

H-1 PV EXPRESSING RNAi EFFECTORS

The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs against the PD-L1 gene which display improved anticancer activity. These new viruses are based on the ΔH-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (ΔH-1PV) and harbouring a shRNA expression cassette in which the expression of the shRNA is controlled by the H1 Polymerase III promoter. In this invention the inventors aimed to use the ΔH-1PVsilencer to silence the PD-L1 gene. PD1/PD-L1 negatively regulates T cell-mediated immune responses and serves as a mechanism for tumors to escape antigen-specific T cell immune responses. The present invention also provides cells or organisms comprising said parvovirus.

H-1 pv expressing rnai effectors

The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs against the PD-L1 gene which display improved anticancer activity. These new viruses are based on the ΔH-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (ΔH-1PV) and harbouring a shRNA expression cassette in which the expression of the shRNA is controlled by the H1 Polymerase III promoter. In this invention the inventors aimed to use the ΔH-1PVsilencer to silence the PD-L1 gene. PD1/PD-L1 negatively regulates T cell-mediated immune responses and serves as a mechanism for tumors to escape antigen-specific T cell immune responses. The present invention also provides cells or organisms comprising said parvovirus.

H-1 PV EXPRESSING RNAi EFFECTORS

The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs against the PD-L1 gene which display improved anticancer activity. These new viruses are based on the ΔH-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (ΔH-1PV) and harbouring a shRNA expression cassette in which the expression of the shRNA is controlled by the H1 Polymerase III promoter. In this invention the inventors aimed to use the ΔH-1PVsilencer to silence the PD-L1 gene. PD1/PD-L1 negatively regulates T cell-mediated immune responses and serves as a mechanism for tumors to escape antigen-specific T cell immune responses. The present invention also provides cells or organisms comprising said parvovirus.

自带电容的电机及空调器

本实用新型公开了一种自带电容的电机及空调器，自带电容的电机包括电机壳体和安装有电容的电器盒，所述电器盒相对两个平行侧板上设有伸出的安装耳，所述安装耳上设有安装孔，所述电器盒通过安装耳轴向固定在电机壳体两端的端盖上。本实用新型提出的自带电容的电机可以减少原材料，缩减生产工时，提高工作效率，提高产品质量，杜绝噪音不良及因为自攻螺钉引起的伤线风险。

Detergent recommendation method and device

The present invention belongs to the technical field of smart homes, and particularly relates to a detergent recommendation method and equipment. The invention aims to solve the problems of various adverse effects caused by inappropriate detergent usage of user such as clothes damage and harm to human health. The detergent recommendation method of the present invention includes: obtaining usage numbers respectively corresponding to various types of washing programs used by a user where the various types of washing programs respectively correspond to different types of detergents, selecting N types of washing programs with a maximum usage number from various types of washing programs according to the usage numbers, and pushing a prompt information of detergents respectively corresponding to the N types of the washing programs to the user, and can preferentially recommend the detergent suitable for the washing program with higher operating frequency to the user based on the usage number of the user using different washing programs, so that the user can use suitable detergent for washing and thus avoid various adverse effects caused by inappropriate selection of detergent.

Modified oncolytic parvovirus h-1pv with an enhanced fitness and superior anticancer activity

The present invention relates to a rodent H-1 parvovirus variant capable of propagating and spreading through human tumor cells. In particular, the present invention relates to a parvovirus variant (H-1PV DR) that is based on wild-type H-1 PV but contains a 114-nucleotide internal deletion and a 55-nucleotide repeated motif towards the right-end terminus in the presence of full length of right-end ITRs. This variant displays improved anticancer activity. The present invention also relates to a pharmaceutical composition containing such a parvovirus variant as well as its use for the treatment of cancer.

Anti-thrombogenic medical devices and methods

Systems for treating aneurysms

Devices, systems, and methods for treating aneurysms are disclosed herein. According to some embodiments, the present technology includes a treatment system comprising a delivery shaft, a manipulation shaft slidably positioned within the lumen of the delivery shaft, and an occlusive device configured for implantation within the aneurysm. The occlusive device can comprise a plurality of filaments that are secured to one another at a proximal end of the occlusive device by a cured material. The occlusive device can comprise inner and outer layers of braided filaments, wherein the proximal end region of the inner layer has an exposed portion that extends proximally beyond the proximal end region of the outer layer, and wherein the cured material extends into and fills interstices between the braided filaments at the proximal end regions of the inner and outer layers.

Gastroretentive articles for alcohol sensing

Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).

Devices, systems, and methods for treating aneurysms

Devices, systems, and methods for treating aneurysms are disclosed herein. According to some embodiments, the present technology includes a treatment system comprising a delivery shaft, a manipulation shaft slidably positioned within the lumen of the delivery shaft, and an occlusive device configured for implantation within the aneurysm. The occlusive device can comprise a plurality of filaments that are secured to one another at a proximal end of the occlusive device by a cured material. The occlusive device can comprise inner and outer layers of braided filaments, wherein the proximal end region of the inner layer has an exposed portion that extends proximally beyond the proximal end region of the outer layer, and wherein the cured material extends into and fills interstices between the braided filaments at the proximal end regions of the inner and outer layers.

Manufacturing method of devices for treatment of intracranial aneurysms

Devices, systems, and methods for treatment of intracranial aneurysms

Systems and methods for treating an aneurysm in accordance with embodiments of the present technology include intravascularly delivering an occlusive member to an aneurysm cavity and deforming a shape of the occlusive member via introduction of an embolic element to a space between the occlusive member and an inner surface of the aneurysm wall.

Systems and methods for treating aneurysms

Treatment of aneurysms can be improved by delivering an occlusive member (e.g., an expandable braid) to an aneurysm sac in conjunction with an embolic element (e.g., coils, embolic material). A treatment system for such treatment can include an electrolytically corrodible core wire having a proximal portion, a distal portion, and a detachment zone between the proximal portion and the distal portion. An occlusive member having a proximal hub is coupled to the core wire distal portion. A conduit extends along at least a portion of the core wire. The conduit has a lumen configured to pass an embolic element therethrough.

Live attenuated viral vaccine created by self-attenuation with species-specific artificial microrna

The present invention includes a live attenuated virus and methods of making the same comprising an isolated virus comprising a viral genome that expresses one or more viral antigens; and one or more exogenous species-specific microRNAs inserted into the viral genome and expressed thereby, wherein the species-specific microRNAs are ubiquitously expressed in a viral target species cell but not in a viral propagation cell.

H-1 PV EXPRESSING RNAi EFFECTORS

The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs against the PD-L1 gene which display improved anticancer activity. These new viruses are based on the ΔH-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (ΔH-1PV) and harbouring a shRNA expression cassette in which the expression of the shRNA is controlled by the H1 Polymerase III promoter. In this invention the inventors aimed to use the ΔH-1PVsilencer to silence the PD-L1 gene. PD1/PD-L1 negatively regulates T cell-mediated immune responses and serves as a mechanism for tumors to escape antigen-specific T cell immune responses. The present invention also provides cells or organisms comprising said parvovirus.

Electro-hydraulic proportional valve and shock absorber having continuous damping control

Modified oncolytic parvovirus h-1pv with an enhanced fitness and superior anticancer activity

The present invention relates to a rodent H-1 parvovirus variant capable of propagating and spreading through human tumor cells. In particular, the present invention relates to a parvovirus variant (H-1PV DR) that is based on wild-type H-1 PV but contains a 114-nucleotide internal deletion and a 55-nucleotide repeated motif towards the right-end terminus in the presence of full length of right-end ITRs. This variant displays improved anticancer activity. The present invention also relates to a pharmaceutical composition containing such a parvovirus variant as well as its use for the treatment of cancer.

Anti-thrombogenic medical devices and methods

Methods for forming an expandable tubular body having a plurality of braided filaments including a first filament including platinum or platinum alloy and a second filament including cobalt-chromium alloy. The methods include applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament and applying a silane material on the second filament followed by a second phosphorylcholine material on the silane material on the second filament. The first and second phosphorylcholine materials each define a thickness of less than 100 nanometers.

Application of untranslated regions of a group of influenza virus genes in preparing mrna vaccine

Embolic material delivery device and related technology

A device for treating an intracranial aneurysm in accordance with an embodiment of the present technology includes an elongate conduit body defining an axial lumen through which the conduit body is configured to convey liquid embolic material toward the aneurysm. The conduit body includes a first flexibility zone defining a first average bending stiffness and a first outer diameter. The conduit body further includes a second flexibility zone distal to the first flexibility zone and defining a second average bending stiffness and a second outer diameter. The second average bending stiffness and the second outer diameter are less than the first average bending stiffness and the first outer diameter, respectively. The conduit body also includes a transition zone between the first and second flexibility zones. The transition zone defines a third outer diameter that transitions proximally-to-distally from the first outer diameter to the second outer diameter.

Hinge for photo frame

Air spring assembly

Replication-defective recombinant H9N2 avian influenza virus expressing HA of H5 subtype

A method for preparing a replication-defective recombinant H9N2 avian influenza virus expressing HA of H5N1 subtype, comprising constructing a replication-defective recombinant avian influenza virus steadily expressing surface glycoprotein hemagglutinin (HA) of both H9N2 and H5N1 subtypes and subjecting to replication and packaging in a MDCK cell capable of steadily expressing neuraminidase (NA) of both H9N2 subtype to form a recombinant virus particle. The virus particle can be used to prepare an attenuated vaccine.

Replication-defective recombinant H9N2 avian influenza virus expressing HA of H5 subtype

Live attenuated viral vaccine created by self-attenuation with species-specific artificial microrna

The present invention includes a live attenuated virus and methods of making the same comprising an isolated virus comprising a viral genome that expresses one or more viral antigens; and one or more exogenous species-specific microRNAs inserted into the viral genome and expressed thereby, wherein the species-specific microRNAs are ubiquitously expressed in a viral target species cell but not in a viral propagation cell.

Electro-hydraulic proportional valve and shock absorber having continuous damping control

Disclosed are an electro-hydraulic proportional valve assembly and a continuous damping control damper. The electro-hydraulic proportional valve (3) is provided with a first inlet and outlet (31) and a second inlet and outlet (32), a filter device (4) being arranged in each of the first inlet and outlet (31) and the second inlet and outlet (32); where the filter device (4) includes a housing (41) internally provided with an accommodation cavity, and a filter assembly (42) arranged in the accommodation cavity, and configured to filter oil entering the electro-hydraulic proportional valve (3). The filter devices (4) can prevent impurities in the oil from entering the electro-hydraulic proportional valve (3) effectively and the electro-hydraulic proportional valve (3) can work normally all the time.